Stock listing
NASDAQ:SGMT Sagimet Biosciences Inc. - Series A Stock
Home listing (NASDAQ) of Sagimet Biosciences Inc. - Series A
Follow Sagimet Biosciences Inc. - Series A into a list and get an email when it puts out news.
Share price · NASDAQ:SGMT
$9.08 USD -1.03 (-10.2%)
Close on Nov 20, 2026
- Day range
- $8.83 – $9.40 USDNov 20, 2026
- Volume
- 1.50M sharesNov 20, 2026
- Market cap
- $638.7M USDAt the close on Nov 20, 2026 · price × 70.34M shares outstanding
- 52-week range
- $4.50 – $11.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $12.17M USDMedian day 1.09M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SGMT · Home | $9.08 USD | -1.03 (-10.2%) | 1,500,685 | $9.32 | $9.40 | $8.832 | $10.11 | Close on Nov 20, 2026 |
| Frankfurt:0O2 | €8.50 EUR | -0.48 (-5.3%) | — | €8.60 | €8.62 | €8.50 | €8.98 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SGMT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $9.08 | -1.03 | -10.2% | $9.32 | $9.40 | $8.832 | 1,500,685 | |
| $10.11 | +0.26 | +2.6% | $9.86 | $10.27 | $9.81 | 932,587 | |
| $9.85 | -0.28 | -2.8% | $10.09 | $10.20 | $9.64 | 843,298 | |
| $10.13 | -0.09 | -0.9% | $10.10 | $10.46 | $9.91 | 1,023,998 | |
| $10.22 | -0.71 | -6.5% | $10.84 | $10.84 | $9.96 | 759,442 | |
| $10.93 | -0.48 | -4.2% | $11.11 | $11.31 | $10.81 | 1,440,961 | |
| $11.41 | +0.52 | +4.8% | $10.93 | $11.44 | $10.80 | 1,790,259 | |
| $10.89 | +0.06 | +0.6% | $10.66 | $11.00 | $10.48 | 1,573,139 | |
| $10.83 | +0.98 | +9.9% | $10.01 | $10.86 | $9.70 | 1,093,246 | |
| $9.85 | +0.73 | +8.0% | $9.25 | $9.87 | $9.02 | 857,846 | |
| $9.12 | -0.87 | -8.7% | $9.83 | $9.95 | $9.055 | 1,153,760 | |
| $9.99 | +0.04 | +0.4% | $10.25 | $10.43 | $9.64 | 755,914 | |
| $9.95 | +0.26 | +2.7% | $9.80 | $10.16 | $9.659 | 636,837 | |
| $9.69 | -0.23 | -2.3% | $9.92 | $9.97 | $9.615 | 735,883 | |
| $9.92 | -0.51 | -4.9% | $10.41 | $10.54 | $9.82 | 989,119 | |
| $10.43 | -0.31 | -2.9% | $10.82 | $10.92 | $10.27 | 738,502 | |
| $10.74 | +0.32 | +3.1% | $10.32 | $10.76 | $10.26 | 1,235,069 | |
| $10.42 | +0.86 | +9.0% | $9.58 | $10.48 | $9.55 | 1,108,685 | |
| $9.56 | -0.02 | -0.2% | $9.61 | $9.70 | $9.41 | 767,181 | |
| $9.58 | -0.37 | -3.7% | $9.95 | $9.95 | $9.495 | 694,900 | |
| $9.95 | -0.04 | -0.4% | $10.00 | $10.15 | $9.628 | 1,006,600 | |
| $9.99 | +0.25 | +2.6% | $9.76 | $10.21 | $9.72 | 1,578,100 | |
| $9.74 | +0.88 | +9.9% | $8.88 | $10.15 | $8.83 | 2,175,500 | |
| $8.86 | +0.84 | +10.5% | $8.24 | $9.005 | $8.15 | 1,684,000 | |
| $8.02 | -0.15 | -1.8% | $8.15 | $8.25 | $7.94 | 1,088,900 | |
| $8.17 | +0.625 | +8.3% | $7.61 | $8.275 | $7.54 | 1,367,000 | |
| $7.545 | -0.435 | -5.5% | $7.78 | $8.00 | $7.51 | 1,984,800 | |
| $7.98 | -0.82 | -9.3% | $8.70 | $8.74 | $7.88 | 2,349,300 | |
| $8.80 | -0.13 | -1.5% | $8.85 | $9.145 | $8.735 | 1,156,400 | |
| $8.93 | +0.01 | +0.1% | $8.84 | $9.05 | $8.78 | 763,500 | |
| $8.92 | +0.04 | +0.5% | $8.80 | $8.94 | $8.63 | 1,229,000 | |
| $8.88 | +0.12 | +1.4% | $8.65 | $8.97 | $8.598 | 631,600 | |
| $8.76 | -0.27 | -3.0% | $8.99 | $8.99 | $8.55 | 896,300 | |
| $9.03 | -0.11 | -1.2% | $9.075 | $9.12 | $8.40 | 1,528,700 | |
| $9.14 | -0.23 | -2.5% | $9.26 | $9.38 | $8.88 | 1,712,500 | |
| $9.37 | -0.51 | -5.2% | $9.63 | $10.01 | $9.315 | 2,008,400 | |
| $9.88 | +0.55 | +5.9% | $10.61 | $10.93 | $9.46 | 5,453,100 | |
| $9.33 | -0.61 | -6.1% | $9.92 | $9.92 | $9.25 | 856,800 | |
| $9.94 | +0.70 | +7.6% | $9.15 | $9.95 | $9.025 | 1,345,800 | |
| $9.24 | +0.13 | +1.4% | $9.11 | $9.265 | $8.89 | 1,246,500 | |
| $9.11 | -1.31 | -12.6% | $9.78 | $9.99 | $8.685 | 3,722,700 | |
| $10.42 | -0.67 | -6.0% | $11.23 | $11.26 | $10.15 | 1,115,900 | |
| $11.09 | +0.29 | +2.7% | $10.84 | $11.33 | $10.72 | 874,100 | |
| $10.80 | -0.29 | -2.6% | $11.20 | $11.21 | $10.66 | 753,300 | |
| $11.09 | -0.08 | -0.7% | $11.17 | $11.40 | $10.80 | 1,854,000 | |
| $11.17 | +0.71 | +6.8% | $10.69 | $11.34 | $10.68 | 1,019,100 | |
| $10.46 | 0.00 | 0.0% | $10.51 | $10.62 | $10.25 | 620,600 | |
| $10.46 | -0.42 | -3.9% | $10.81 | $10.84 | $10.31 | 852,700 | |
| $10.88 | 0.00 | 0.0% | $10.96 | $11.10 | $10.82 | 516,700 | |
| $10.88 | -0.18 | -1.6% | $11.33 | $11.35 | $10.77 | 639,400 | |
| $11.06 | +0.20 | +1.8% | $10.75 | $11.45 | $10.67 | 937,700 | |
| $10.86 | +0.15 | +1.4% | $11.25 | $11.27 | $10.69 | 1,249,900 | |
| $10.71 | -0.23 | -2.1% | $10.84 | $11.17 | $10.65 | 805,400 | |
| $10.94 | +0.02 | +0.2% | $10.79 | $10.98 | $10.53 | 1,250,100 | |
| $10.92 | -0.07 | -0.6% | $11.21 | $11.24 | $10.62 | 1,142,100 | |
| $10.99 | +0.49 | +4.7% | $10.51 | $11.06 | $10.51 | 1,798,000 | |
| $10.50 | +0.24 | +2.3% | $10.15 | $10.72 | $10.15 | 752,200 | |
| $10.26 | -0.29 | -2.7% | $10.36 | $10.44 | $10.21 | 688,400 | |
| $10.55 | -0.20 | -1.9% | $10.62 | $10.81 | $10.47 | 574,000 | |
| $10.75 | -0.11 | -1.0% | $10.90 | $10.95 | $10.54 | 657,600 | |
| $10.86 | +0.57 | +5.5% | $10.26 | $10.87 | $10.11 | 1,236,700 | |
| $10.29 | +0.08 | +0.8% | $10.38 | $10.60 | $10.20 | 968,555 | |
| $10.21 | -0.04 | -0.4% | $10.13 | $10.51 | $9.95 | 1,242,184 | |
| $10.25 | +0.07 | +0.7% | $10.22 | $10.48 | $10.06 | 1,022,300 | |
| $10.18 | -0.40 | -3.8% | $10.48 | $10.64 | $10.15 | 1,138,700 |
- Ticker
- NASDAQ:SGMT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Latest deck · Nov 12, 2026
Sagimet Biosciences — Investor Presentation (November 2026)
Investor deck · 33 slides
Latest news
Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Nov 12, 2026
Closed $10.93 (-4.2%) on Nov 12, 2026
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Oct 29, 2026
Closed $10.43 (-2.9%) on Oct 29, 2026
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
Oct 22, 2026
Closed $9.95 (-0.4%) on Oct 22, 2026
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
Oct 9, 2026
Closed $8.93 (+0.1%) on Oct 9, 2026
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
Oct 1, 2026
Closed $9.14 (-2.5%) on Oct 2, 2026
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
Sep 30, 2026
Closed $9.88 (+5.9%) on Sep 30, 2026
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
Sep 30, 2026
Closed $9.88 (+5.9%) on Sep 30, 2026
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
Sep 28, 2026
Closed $9.94 (+7.6%) on Sep 28, 2026
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
Aug 25, 2026
Closed $10.29 (+0.8%) on Aug 25, 2026
Sagimet Biosciences Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
Aug 18, 2026
Closed $10.58 (+1.4%) on Aug 18, 2026
Sagimet Biosciences Inc. - Series A on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 33 in the last 12 months · 91 in all · newest Nov 12, 2026 · oldest 2023
- Decks
- 34 decks · latest Nov 12, 2026
Where Sagimet Biosciences Inc. - Series A is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SGMT · Home listing · This page | NASDAQ | United States | USD |
| gettex:0O2 | gettex | Germany | EUR |
| BOATS:SGMT | BOATS | United States | USD |
| Lang & Schwarz:A3CPAM | Lang & Schwarz | Germany | EUR |
| LS Exchange:A3CPAM | LS Exchange | Germany | EUR |
| Munich:0O2 | Munich | Germany | EUR |
| Dusseldorf:0O2 | Dusseldorf | Germany | EUR |
| Tradegate:0O2 | Tradegate | Germany | EUR |
| Frankfurt:0O2 | Frankfurt | Germany | EUR |
| Stuttgart:0O2 | Stuttgart | Germany | EUR |
Valuation
Price/book 2.6× against a median of 4.3×: 4th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $404.3M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 2.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.96
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT | US$638.7M | US$404.3M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.96 |
| Sun Pharma Advanced Research Co. Ltd. · NSE:SPARC | US$666.0M | US$519.1M | 3.8× | 2.5× | 2.9× | 4.3× | 84.7% | 0.0× | n/a |
| Oscotec Inc. · KRX:039200 | US$660.9M | US$660.9M | 11.6× | 6.3× | n/a | 4.5× | 54.0% | 0.0× | n/a |
| Shouyao Holdings Beijing Co. Ltd. Class A · SSE:688197 | US$648.7M | US$566.3M | n/a | 37.8× | n/a | 6.8× | −18.6% | 0.0× | n/a |
| Prime Medicine, Inc. · NASDAQ:PRME | US$645.8M | US$695.1M | n/a | 98.4× | n/a | 76.5× | n/a | 13.1× | 2.28 |
| Gubra A/S · OMXCOP:GUBRA | US$639.2M | US$534.2M | 2.6× | 1.4× | 1.7× | 4.2× | 64.1% | 0.2× | n/a |
| Kura Oncology, Inc. · NASDAQ:KURA | US$634.9M | US$152.6M | n/a | 1.9× | n/a | 35.4× | −369.3% | 0.6× | 1.30 |
| Alphamab Oncology · HKEX:9966 | US$628.9M | US$454.4M | n/a | 5.5× | n/a | 2.5× | −20.1% | 0.2× | n/a |
| Iambic Therapeutics, Inc. · NASDAQ:IAM | US$621.4M | US$369.4M | n/a | 39.2× | n/a | n/a | −820.0% | n/a | n/a |
| Janux Therapeutics, Inc. · NASDAQ:JANX | US$616.7M | −US$308.6M | n/a | −13.3× | n/a | 0.7× | −428.7% | 0.0× | 0.95 |
| Olema Pharmaceuticals, Inc. · NASDAQ:OLMA | US$615.0M | US$204.6M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.25 |
| Median of the others | US$637.0M | US$486.7M | 3.8× | 5.5× | 2.3× | 4.3× | −19.4% | 0.0× | 1.27 |
Forecasts
9 strong buy · 2 buy · 1 strong sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 27.27 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.25 · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| David Happel | Chief Executive Officer & Director |
| Thierry Chauche | Chief Financial Officer |
| Elizabeth Rozek | Chief Legal & Administrative Officer |
| Robert D’Urso | Senior Vice President of New Products |
| Andreas Grauer | Chief Medical Officer |
| Marie O’Farrell | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| George Kemble | Chair |
| Anne Phillips | Board Member |
| Beth Seidenberg | Lead Independent Director |
| David Happel | Chief Executive Officer & Director |
| Elizabeth Grammer | Board Member |
| Jennifer Jarrett | Board Member |
| Paul Hoelscher | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −4.2% |
| Q2 2026 | Aug 11, 2026 · Before open | −0.5% |
| Q1 2026 | May 12, 2026 · Before open | −0.5% |
| Q4 2025 | Mar 11, 2026 | −3.4% |
| Q3 2025 | Nov 13, 2025 · Before open | −12.2% |
| Q2 2025 | Aug 13, 2025 · Before open | +0.3% |
| Q1 2025 | May 8, 2025 | −2.4% |
| Q4 2024 | Mar 12, 2025 · Before open | +3.4% |
| Q3 2024 | Nov 14, 2024 · Before open | −13.9% |
| Q2 2024 | Aug 14, 2024 · Before open | −7.1% |
All 15 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · Before open | +5.5% |
| Q4 2023 | Mar 25, 2024 · Before open | +15.7% |
| Q3 2023 | Nov 13, 2023 · Before open | −13.7% |
| Q2 2023 | Aug 21, 2023 · After close | −13.7% |
| Q1 2023 | May 31, 2023 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Sagimet Biosciences — Investor Presentation (November 2026) | Investor deck | 33 slides | Nov 12, 2026 |
| Sagimet Biosciences — Investor Presentation (October 2026) | Investor deck | 31 slides | Oct 22, 2026 |
| Sagimet Biosciences — Investor Presentation (September 2026) | Investor deck | 30 slides | September 2026 |
| Sagimet Biosciences — Corporate Update (August 2026) | Corporate update | 22 slides | Aug 11, 2026 |
| Sagimet Biosciences — Investor Presentation (July 2026) | Investor deck | 22 slides | Jul 21, 2026 |
| Sagimet Biosciences — Corporate Update (April 2026) | Corporate update | 22 slides | Apr 30, 2026 |
| Sagimet Biosciences — Investor Presentation (April 2026) | Investor deck | 22 slides | Apr 27, 2026 |
| Sagimet Biosciences — Technical Presentation (April 2026) | Technical | 17 slides | Apr 15, 2026 |
| Sagimet Biosciences — Corporate Update (March 2026) | Corporate update | 52 slides | Mar 11, 2026 |
| Sagimet Biosciences — Investor Presentation (February 2026) | Investor deck | 52 slides | Feb 2, 2026 |
All 34 decks
IPO
Priced at US$16.00 a share on Jul 13, 2023.
- Price
- US$16.00 a share
- Shares offered
- 5,312,500 shares of common stock
- Offering size
- US$85 million
- Underwriters' option
- Up to 796,875 more shares
- Listing
- SGMT on the Nasdaq Global Market
- Underwriters
- Goldman Sachs & Co. LLC, TD Cowen, Piper Sandler, JMP Securities · In the order on the cover
- Shares delivered
- On or about Jul 18, 2023
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 24, 2023 |
| Filed publicly | Jun 23, 2023 |
| Amended twice | Newest Jul 10, 2023 |
| Shares registered with an exchange | Jul 11, 2023 |
| Declared effective by the SEC | Jul 13, 2023 |
| Final prospectus, with the price | Jul 17, 2023 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 17, 2023 |
| EFFECT · Notice that a registration is effective | Jul 13, 2023 |
| S-1MEF · Registration of more shares for the same offering | Jul 13, 2023 |
| CERT · Exchange's certificate of listing | Jul 13, 2023 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 11, 2023 |
| CORRESP · Letter to the SEC | Jul 11, 2023 |
| CORRESP · Letter to the SEC | Jul 11, 2023 |
| CORRESP · Letter to the SEC | Jul 10, 2023 |
| S-1/A · Registration statement, amended | Jul 10, 2023 |
| UPLOAD · Letter from the SEC | Jul 6, 2023 |
All 18 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jul 3, 2023 |
| S-1 · Registration statement | Jun 23, 2023 |
| DRS/A · Draft registration statement, amended | May 11, 2023 |
| DRSLTR · Letter to the SEC with a draft | May 10, 2023 |
| DRSLTR · Letter to the SEC with a draft | Apr 25, 2023 |
| DRS/A · Draft registration statement, amended | Apr 25, 2023 |
| UPLOAD · Letter from the SEC | Apr 20, 2023 |
| DRS · Draft registration statement | Mar 24, 2023 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 17, 2023
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2.00M | 0 | 0 | 0 | 0 |
| Cost of revenue | 130.0K | 134.0K | 124.0K | 88.0K | |||
| Gross profit | 2.00M | -130.0K | -134.0K | -124.0K | -88.0K | ||
| Research and development | 39.1M | 38.4M | 19.8M | 24.9M | 19.3M | 8.18M | 8.39M |
| Selling, general and administrative | 17.8M | 16.0M | 13.0M | 6.14M | 4.38M | 3.22M | 5.86M |
| Operating income | -56.9M | -54.5M | -30.7M | -31.1M | -23.7M | -11.4M | -14.2M |
| Depreciation and amortization | 30.7M | 130.0K | 134.0K | 124.0K | 1.00K | ||
| EBITDA | 0 | -30.9M | -23.6M | -11.3M | -14.2M | ||
| Interest expense | 0 | 64.0K | |||||
| Income before tax | -51.0M | -45.6M | -27.9M | -30.5M | -24.4M | -11.4M | -14.3M |
| Income tax | 0 | 0 | -2.86M | -31.6M | -23.7M | -176.3K | -9.00K |
| Net income | -51.0M | -45.6M | -27.9M | -30.5M | -24.4M | -11.4M | -14.3M |
| Earnings per share, basic | -1.58 | -1.45 | -2.66 | -165.20 | -1.10 | -0.51 | -0.64 |
| Earnings per share, diluted | -1.58 | -1.45 | -2.66 | -165.20 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 35.0M | 75.8M | 75.1M | 158.0K | 56.7M | 68.7M | 10.2M |
| Short-term investments | 78.1M | 75.4M | 19.8M | 32.2M | 0 | ||
| Current assets | 116.4M | 152.8M | 96.6M | 32.8M | 58.7M | 68.7M | 10.8M |
| Property, plant and equipment | 194.0K | 318.0K | |||||
| Total assets | 116.5M | 160.3M | 96.7M | 33.0M | 59.0M | 69.0M | 11.2M |
| Accounts payable | 1.31M | 1.43M | 186.0K | 1.13M | 761.0K | 513.0K | 1.20M |
| Current liabilities | 5.10M | 4.45M | 5.65M | 5.28M | 2.44M | 1.91M | 2.08M |
| Total debt | 78.0K | 78.0K | 65.0K | 211.0K | 348.0K | 210.0K | 341.0K |
| Total liabilities | 5.10M | 4.45M | 5.65M | 5.36M | 217.3M | 204.9M | 136.5M |
| Shareholders' equity | 111.4M | 155.8M | 91.1M | -186.9M | -158.3M | -135.9M | -125.3M |
| Shares outstanding | 32.3M | 31.4M | 0 | 185.1K | 22.2M | 22.2M | 22.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -45.6M | -42.4M | -23.8M | -24.5M | -21.7M | -10.4M | -10.6M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | -45.6M | -42.4M | -23.8M | -24.5M | -21.7M | -10.4M | -10.6M |
| Cash from investing | 4.56M | -61.7M | 12.6M | -32.0M | 20.0K | -27.0K | |
| Cash from financing | 275.0K | 104.8M | 86.2M | -73.0K | 9.74M | 68.9M | 18.5M |
| Change in cash | 1.60M | -11.1M | 1.88M | 101.7M | -12.0M | 58.5M | 7.91M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 22, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 7, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 30, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Sep 30, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 30, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 424B3 · Prospectus | Sep 30, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 20, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Jul 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 3, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 14, 2026 | Insider trade | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 28, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Apr 28, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 27, 2026 | Current report | SEC |
| 8-K · Current report | Apr 27, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 21, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 21, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 21, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 11, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 11, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 11, 2026 | Results | SEC |
| 10-K · Annual report | Mar 11, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 2, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 18, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 18, 2025 | Current report | SEC |
| 8-K · Current report | Dec 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 23, 2025 | Current report | SEC |
| 8-K · Current report | Aug 22, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 14, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Aug 14, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 24, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 4, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 20, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| UPLOAD · Letter from the SEC | May 7, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 5, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 30, 2025 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Apr 22, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 12, 2025 | Results | SEC |
| 10-K · Annual report | Mar 12, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 14, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 2, 2025 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Aug 27, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 22, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 19, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 16, 2024 | Material contract | SEC |
| S-3 · Registration statement | Aug 15, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 1, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jul 25, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 23, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2024 | Current report | SEC |
| 8-K/A · Current report, amended | Jun 13, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2024 | Meeting outcome | SEC |
| 8-K · Current report | May 23, 2024 | Current report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 8, 2024 | Insider trade | SEC |
| 8-K · Current report | May 6, 2024 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 18, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 18, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 18, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 25, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 11, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 5, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 2, 2024 | Management or board change | SEC |
| 3 · Initial statement of ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 30, 2024 | Current report | SEC |
| 424B4 · Prospectus | Jan 26, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 26, 2024 | Other filings | SEC |
| 8-K · Current report | Jan 24, 2024 | Results | SEC |
| S-1/A · Registration statement, amended | Jan 24, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 23, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jan 23, 2024 | Offer document | SEC |
| 8-K · Current report | Jan 22, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jan 16, 2024 | Other filings | SEC |
| DRS · Draft registration statement | Jan 10, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 29, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 21, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Nov 20, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 23, 2023 | Current report | SEC |
| 8-K · Current report | Sep 27, 2023 | Current report | SEC |
| SC 13G · Big-stake notice | Sep 11, 2023 | Big-stake notice | SEC |
This page holds 200 of 267 filings. Open Filings
Cap table
Built by 6ix from Sagimet Biosciences Inc. - Series A’s releases
- Common shares
- 70,341,169
- Fully diluted
- 70,341,169
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 70,341,169 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 70,341,169 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Timothy P. Walbert Other companies: Latigo Biotherapeutics, Inc. (Chair, Board of Directors · Since at least Aug 6, 2026); Kardigan, Inc. (Board of Directors · Since at least Jun 17, 2026); Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); BioMarin Pharmaceutical Inc. (Director · Since at least Feb 24, 2025); Mirum Pharmaceuticals, Inc. (Director · Since at least Apr 5, 2023); Century Therapeutics, Inc. (Director · Since at least Oct 1, 2022); Aurinia Pharmaceuticals Inc (Director · Jan 1, 2021 – May 18, 2022 · Past); Assertio Holdings, Inc. (Director · May 20, 2020 – May 20, 2020 · Past); Exicure, Inc. (Director · Jul 22, 2019 – Jun 2, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Oct 12, 2015 – Feb 13, 2018 · Past); Egalet Corporation (Director · Mar 10, 2014 – May 20, 2020 · Past); Horizon Pharma PLC (Chairman, President and CEO, Director · Jul 28, 2011 – Mar 23, 2019 · Past); Raptor Pharmaceutical Corp (Director · Apr 11, 2011 – Mar 13, 2014 · Past); Idm Pharma Inc (President and CEO, Director · May 25, 2007 – Apr 3, 2008 · Past) | Director · Since at least Apr 1, 2024 |
| Beth C Seidenberg Other companies: Latigo Biotherapeutics, Inc. (Director · Since at least Aug 6, 2026); Kyverna Therapeutics, Inc. (Director · Since at least Feb 7, 2024); Vera Therapeutics, Inc. (Director · Since at least May 13, 2021); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Progyny, Inc. (Director · Oct 24, 2019 – May 23, 2024 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); Atara Biotherapeutics, Inc. (Director · Oct 15, 2014 – May 31, 2023 · Past); Epizyme Inc (Director · May 30, 2013 – Jun 30, 2019 · Past); Tesaro Inc (Director · Jun 27, 2012 – Jan 22, 2019 · Past) | Director · Since at least Jul 13, 2023 |
| Jennifer Jarrett Other companies: Damora Therapeutics, Inc. (President and Chief Executive Officer in March 2026, Board Director · Since at least Mar 30, 2026); Zura Bio Limited (Director · Since at least Mar 20, 2023); Syndax Pharmaceuticals, Inc. (Director · Since at least Sep 25, 2018); Arcus Biosciences, Inc. (Chief Operating Officer · Since at least Mar 14, 2018); Radius Health, Inc. (Director · May 18, 2022 – Aug 15, 2022 · Past); Surrozen, Inc. (Director · Nov 18, 2020 – Nov 18, 2020 · Past); Arena Pharmaceuticals Inc (Director · Jun 13, 2017 – Mar 11, 2022 · Past); Audentes Therapeutics Inc (Director · Jun 12, 2017 – Jan 15, 2020 · Past); Medivation Inc (Chief Financial Officer · Apr 7, 2016 – Sep 28, 2016 · Past) | Board Member · Since at least Aug 1, 2024 |
| Richard Rodgers Other companies: Novavax, Inc. (Director · Since at least Oct 29, 2022); Opus Genetics, Inc. (Director · Since at least Dec 2, 2014); Ardelyx, Inc. (Director · Since at least Jun 18, 2014); Tesaro Inc (Executive VP & CFO · Jun 27, 2012 – Mar 6, 2013 · Past); Abraxis BioScience Inc (Senior Vice President and CFO · Jul 9, 2009 – Jul 13, 2009 · Past); Mgi Pharma Inc (Sr. VP and Controller · Jul 15, 2006 – Jan 28, 2008 · Past) | Director · Jul 13, 2023 – Jul 18, 2023 · Past |
| Anne Phillips Other companies: vTv Therapeutics Inc. (Director · Since at least Mar 13, 2024); Trevena, Inc. (Member of Nominating and Corporate Governance Committee · Since at least Dec 16, 2014); Vaccitech plc (Director · Apr 29, 2021 – May 11, 2023 · Past); AMAG Pharmaceuticals Inc (Director · Apr 10, 2019 – Nov 16, 2020 · Past) | Board Member · Since at least Aug 1, 2024 |
| Merdad Parsey Other companies: Ardelyx, Inc. (Director · Since at least Apr 28, 2025); ArriVent BioPharma, Inc. (Director · Since at least Apr 28, 2025); Arcus Biosciences, Inc. (Director · Jul 13, 2020 – Jul 13, 2020 · Past); Gilead Sciences, Inc. (Chief Medical Officer · Nov 1, 2019 – Dec 10, 2024 · Past) | Director · Jul 13, 2023 – Jun 5, 2024 · Past |
| Beth Seidenberg Other companies: Vera Therapeutics, Inc. (Founding Managing Director, Westlake Village BioPartners · Since at least Nov 4, 2026); Latigo Biotherapeutics, Inc. (Founding Managing Director, Westlake BioPartners · Since at least Aug 10, 2026); Kyverna Therapeutics, Inc. (Independent Director · Since at least May 29, 2026) | Lead Independent Director · Since at least Nov 4, 2026 |
| David Happel Other companies: Horizon Pharma PLC (EVP, Commercial Dev & Strategy · Nov 4, 2016 – Oct 25, 2017 · Past); Raptor Pharmaceutical Corp (Chief Commercial Officer · Oct 20, 2014 – Oct 24, 2016 · Past) | Chief Executive Officer & Director · Since at least Jul 13, 2023 |
| Dennis Hom Other companies: ProQR Therapeutics N.V. (Chief Financial Officer · Since at least Apr 14, 2025); Achaogen Inc (VP, Finance and Corp. Dev. · Mar 11, 2014 – Mar 11, 2014 · Past) | Chief Financial Officer · Jul 13, 2023 – Jul 18, 2023 · Past |
| Paul Hoelscher Other companies: OnKure Therapeutics, Inc. (Director · Jan 20, 2022 – Jun 6, 2023 · Past); Horizon Pharma PLC (EVP, CFO · Jun 23, 2014 – Mar 23, 2019 · Past) | Board Member · Since at least Apr 1, 2024 |
All 21 people
| Person | Seat |
|---|---|
| Andreas Grauer Other companies: Corcept Therapeutics Incorporated (Chief Medical Officer · Mar 18, 2019 – Feb 5, 2021 · Past) | Chief Medical Officer · Since at least Apr 20, 2026 |
| Elizabeth Grammer Other companies: Ardelyx, Inc. (See Remarks · Since at least Jun 18, 2014) | Board Member · Since at least Jul 13, 2023 |
| Thierry Chauche Other companies: Provention Bio Inc (Chief Financial Officer · Dec 1, 2021 – Apr 27, 2023 · Past) | Chief Financial Officer · Since at least May 6, 2024 |
| Anthony M Rimac | Chief Operating Officer · Jul 13, 2023 – Jul 18, 2023 · Past |
| Eduardo Bruno Martins | Chief Medical Officer · Since at least Jul 13, 2023 |
| Elizabeth Rozek | Chief Legal & Administrative Officer · Since at least Jul 13, 2023 |
| George Kemble | Chair · Since at least Jul 13, 2023 |
| Jinzi Jason Wu | Director · Jul 13, 2023 – Jul 18, 2023 · Past |
| Joseph Oriti | See Remarks · Feb 1, 2024 – Feb 1, 2024 · Past |
| Marie O’Farrell | Chief Scientific Officer · Since at least Jan 6, 2025 |
| Robert D’Urso | Senior Vice President of New Products · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Sagimet Biosciences Inc. - Series A.